Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 160

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice

Gengler, Simon, McClean, Paula L., McCurtin, Ruth, Gault, Victor A., Hölscher, Christian·2012·Neurobiology of Aging

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2010.02.014

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 54

  1. Abbas, 2009, Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease, Behav. Brain Res, 205, 265, 10.1016/j.bbr.2009.06.035 · DOI · Paper page
  2. Aubert-Pouessel, 2004, In vitro study of GDNF release from biodegradable PLGA microspheres, J. Control. Release, 95, 463, 10.1016/j.jconrel.2003.12.012 · DOI
  3. Azzouz, 2004, VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model, Nature, 429, 413, 10.1038/nature02544 · DOI · Paper page
  4. Biessels, 2006, Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus, J. Neurol. Neurosurg. Psychiatry, 77, 304, 10.1136/jnnp.2005.069583 · DOI
  5. Biswas, 2008, Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction, Neurochem. Res, 33, 1845, 10.1007/s11064-008-9646-4 · DOI
  6. Blurton-Jones, 2009, Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease, Proc. Natl. Acad. Sci. U. S. A., 106, 13594, 10.1073/pnas.0901402106 · DOI · Paper page
  7. Bondolfi, 2002, Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice, J. Neurosci, 22, 515, 10.1523/JNEUROSCI.22-02-00515.2002 · DOI · Paper page
  8. Bradbury, 2005, Hope for AD with NGF gene-therapy trial, Lancet Neurol, 4, 335, 10.1016/S1474-4422(05)70086-7 · DOI
  9. Carro, 2004, Insulin-like growth factor I and Alzheimer's disease: therapeutic prospects?, In Expert Rev. Neurother, 4, 79, 10.1586/14737175.4.1.79 · DOI
  10. Carro, 2004, The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease, Eur. J. Pharmacol, 490, 127, 10.1016/j.ejphar.2004.02.050 · DOI · Paper page
  11. Chen, 1996, Synaptic release rather than failure in the conditioning pulse results in paired-pulse facilitation during minimal synaptic stimulation in the rat hippocampal CA1 neurones, Neurosci. Lett, 218, 204, 10.1016/S0304-3940(96)13149-9 · DOI
  12. Clarris, 1994, Secretion of nerve growth factor from septum stimulates neurite outgrowth and release of the amyloid protein precursor of Alzheimer's disease from hippocampal explants, J. Neurosci. Res, 38, 248, 10.1002/jnr.490380303 · DOI
  13. Covaceuszach, 2009, Development of a non invasive NGF-based therapy for Alzheimer's disease, Curr. Alzheimer Res, 6, 158, 10.2174/156720509787602870 · DOI
  14. Cummings, 2002, Optimization of techniques for the maximal detection and quantification of Alzheimer's-related neuropathology with digital imaging, Neurobiol. Aging, 23, 161, 10.1016/S0197-4580(01)00316-5 · DOI
  15. Dickson, 1997, The pathogenesis of senile plaques, J. Neuropathol. Exp. Neurol, 56, 321, 10.1097/00005072-199704000-00001 · DOI · Paper page
  16. Gault, 2008, GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid, Eur. J. Pharmacol, 587, 112, 10.1016/j.ejphar.2008.03.025 · DOI
  17. Gault, 2003, Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes, Biochem. Biophys. Res. Commun, 308, 207, 10.1016/S0006-291X(03)01361-5 · DOI
  18. Gault, 2008, GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid, Eur. J. Pharmacol, 587, 112, 10.1016/j.ejphar.2008.03.025 · DOI
  19. Gengler, 2007, Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25–35) are dependent on stimulation-protocol and genetic background, Exp. Brain Res, 179, 621, 10.1007/s00221-006-0819-6 · DOI
  20. Gengler, 2010, Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer's disease is impaired in old but not young mice, PLoS ONE, 10.1371/journal.pone.0009764 · DOI · Paper page
  21. Gilman, 2003, Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons, J. Neurochem, 87, 1137, 10.1046/j.1471-4159.2003.02073.x · DOI
  22. Green, 2007, Incretin hormone mimetics and analogues in diabetes therapeutics, Best Pract. Res. Clin. Endocrinol. Metab, 21, 497, 10.1016/j.beem.2007.09.003 · DOI
  23. Green, 2004, Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid, Arch. Biochem. Biophys, 428, 136, 10.1016/j.abb.2004.05.005 · DOI
  24. Green, 2005, A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, Diabetes Obes. Metab, 7, 595, 10.1111/j.1463-1326.2004.00455.x · DOI
  25. Gregory-Evans, 2009, Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration, Mol. Vis, 15, 962
  26. Heese, 2006, Nerve growth factor, neural stem cells and Alzheimer's disease, Neuro Signals, 15, 1, 10.1159/000094383 · DOI
  27. Hoyer, 2004, Glucose metabolism and insulin receptor signal transduction in Alzheimer disease, Eur. J. Pharmacol, 490, 115, 10.1016/j.ejphar.2004.02.049 · DOI · Paper page
  28. Hwang, 2009, Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice, Gene Ther, 16, 1234, 10.1038/gt.2009.80 · DOI
  29. Hölscher, 2007, Soluble beta-amyloid[25–35] reversibly impairs hippocampal synaptic plasticity and spatial learning, Eur. J. Pharmacol, 561, 85, 10.1016/j.ejphar.2007.01.040 · DOI
  30. Hölscher, 2008, New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's Disease?, Neurobiol. Aging
  31. Kastin, 2003, Entry of exendin-4 into brain is rapid but may be limited at high doses, Int. J. Obes. Relat. Metab. Disord, 27, 313, 10.1038/sj.ijo.0802206 · DOI · Paper page
  32. Kordower, 1997, Cellular delivery of NGF does not alter the expression of beta-amyloid immunoreactivity in young or aged nonhuman primates, Exp. Neurol, 145, 586, 10.1006/exnr.1997.6492 · DOI
  33. Lee, 2007, Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model, PLoS ONE, 2, e156, 10.1371/journal.pone.0000156 · DOI · Paper page
  34. Leech, 1997, Insulinotropic glucagon-like peptide-1-mediated activation of non-selective cation currents in insulinoma cells is mimicked by maitotoxin, J. Biol. Chem, 272, 17987, 10.1074/jbc.272.29.17987 · DOI
  35. Li, 2007, Common pathological processes in Alzheimer Disease and Type 2 Diabetes: a review, Brain Res. Rev, 56, 384, 10.1016/j.brainresrev.2007.09.001 · DOI · Paper page
  36. Luchsinger, 2004, Hyperinsulinemia and risk of Alzheimer disease, Neurology, 63, 1187, 10.1212/01.WNL.0000140292.04932.87 · DOI · Paper page
  37. Nagano, 2005, Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis, Neurol Rev, 27, 768
  38. Okamoto, 1994, Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction, J. Biol. Chem, 269, 1231, 10.1016/S0021-9258(17)42247-2 · DOI · Paper page
  39. Paresce, 1997, Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells, J. Biol. Chem, 14, 29390, 10.1074/jbc.272.46.29390 · DOI · Paper page
  40. Perry, 2003, Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron, J. Neurosci. Res, 72, 603, 10.1002/jnr.10611 · DOI · Paper page
  41. Perry, 2004, A new Alzheimer's disease interventive strategy: GLP-1, Curr. Drug Targets, 5, 565, 10.2174/1389450043345245 · DOI
  42. Poon, 2009, beta-Amyloid impairs axonal BDNF retrograde trafficking, Neurobiol. Aging
  43. Ristow, 2004, Neurodegenerative disorders associated with diabetes mellitus, J. Mol. Med, 82, 510, 10.1007/s00109-004-0552-1 · DOI · Paper page
  44. Sarkar, 2003, Glucagon like peptide-1 (7–36) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus, Brain Res, 985, 163, 10.1016/S0006-8993(03)03117-2 · DOI
  45. Schulte-Herbruggen, 2007, Neurotrophic factors − a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases?, Curr. Med. Chem, 14, 2318, 10.2174/092986707781745578 · DOI
  46. Shi, 2005, Differential effects of aging and insulin-like growth factor-1 on synapses in CA1 of rat hippocampus, Cereb. Cortex, 15, 571, 10.1093/cercor/bhh158 · DOI
  47. Sorenson, 2008, Subcutaneous IGF-1 is not beneficial in 2-year ALS trial, Neurology, 71, 1770, 10.1212/01.wnl.0000335970.78664.36 · DOI · Paper page
  48. Suzuki, 1997, Localization of the ATP-sensitive K+ channel subunit Kir62 in mouse pancreas, Diabetes, 46, 1440, 10.2337/diab.46.9.1440 · DOI
  49. Terzi, 2008, Adeno-associated virus-mediated gene delivery approaches for the treatment of CNS disorders, Biotechnol. J, 3, 1555, 10.1002/biot.200800284 · DOI
  50. Tsai, 2008, Seizures induced by GABAB-receptor blockade in early-life induced long-term GABA(B) receptor hypofunction and kindling facilitation, Epilepsy Res, 79, 187, 10.1016/j.eplepsyres.2008.02.001 · DOI
  51. Wheeler, 1994, Roles of N-type and Q-type Ca2+ channels in supporting hippocampal synaptic transmission, Science, 264, 107, 10.1126/science.7832825 · DOI · Paper page
  52. Wilcock, 2006, Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain, Nat. Protoc, 1, 1591, 10.1038/nprot.2006.277 · DOI · Paper page
  53. Winder, 1993, Activation of metabotropic glutamate receptors increases cAMP accumulation in hippocampus by potentiating responses to endogenous adenosine, J. Neurosci, 13, 38, 10.1523/JNEUROSCI.13-01-00038.1993 · DOI
  54. Zuccato, 2009, Brain-derived neurotrophic factor in neurodegenerative diseases, Natl. Rev. Neurol, 5, 311, 10.1038/nrneurol.2009.54 · DOI · Paper page

Cited by

See all 160

Metadata

Authors
Gengler, S., McClean, P. L., McCurtin, R., Gault, V. A., & Hölscher, C.
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2012-02
Volume
33
Issue
2
Pages
265-276
ISSN
0197-4580 (ISSN-L)
OpenAlex
W2065789765
Cited by
160
References
8
FWCI
9.13
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. https://app.cochat.ai/papers/10.1016/j.neurobiolaging.2010.02.014
The paper
Gengler, S., McClean, P. L., McCurtin, R., Gault, V. A., & Hölscher, C. (2012). Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiology of Aging. https://doi.org/10.1016/j.neurobiolaging.2010.02.014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.